Why Did SoundHound AI Stock Go Up?
SoundHound AI (NASDAQ:SOUN) has moved higher in recent days, breaking…
Buy
57
ADMA Quote, Financials, Valuation and Earnings
Last price:
$17.39
Seasonality move
:
10.05%
Day range:
$17.24 - $17.79
52-week range:
$13.50 - $25.67
Dividend yield:
0%
P/E ratio:
20.43x
P/S ratio:
8.76x
P/B ratio:
9.60x
Volume:
2.3M
Avg. volume:
2.3M
1-year change:
5.65%
Market cap:
$4.1B
Revenue:
$426.5M
EPS (TTM):
$0.85
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ADMA
ADMA Biologics, Inc.
|
$139.8M | $0.20 | 23.95% | 81.82% | $25.67 |
|
ALDX
Aldeyra Therapeutics, Inc.
|
$24.3M | -$0.15 | -- | -44.74% | $9.67 |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$110.8M | $0.08 | 55.26% | -88.43% | $31.63 |
|
CRMD
CorMedix, Inc.
|
$126.7M | $0.80 | 195.3% | 90.44% | $15.57 |
|
MRKR
Marker Therapeutics, Inc.
|
$682K | -$0.19 | -69.71% | -54.94% | $7.87 |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$59.3M | -- | 23.5% | -- | $13.63 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ADMA
ADMA Biologics, Inc.
|
$17.40 | $25.67 | $4.1B | 20.43x | $0.00 | 0% | 8.76x |
|
ALDX
Aldeyra Therapeutics, Inc.
|
$5.22 | $9.67 | $314M | -- | $0.00 | 0% | -- |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$26.65 | $31.63 | $3.3B | -- | $0.00 | 0% | 10.71x |
|
CRMD
CorMedix, Inc.
|
$7.44 | $15.57 | $586.2M | 3.62x | $0.00 | 0% | 2.51x |
|
MRKR
Marker Therapeutics, Inc.
|
$2.04 | $7.87 | $34M | -- | $0.00 | 0% | 5.53x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$8.10 | $13.63 | $478.7M | -- | $0.00 | 0% | 2.24x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ADMA
ADMA Biologics, Inc.
|
16.16% | -3.305 | 2.38% | 3.53x |
|
ALDX
Aldeyra Therapeutics, Inc.
|
23.99% | 2.161 | 4.95% | 2.64x |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
41.85% | -0.649 | 5.02% | 3.07x |
|
CRMD
CorMedix, Inc.
|
1.16% | 2.954 | 0.48% | 1.60x |
|
MRKR
Marker Therapeutics, Inc.
|
-- | 1.778 | -- | 5.66x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
2.29% | -0.960 | 3.7% | 2.92x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ADMA
ADMA Biologics, Inc.
|
$75.6M | $51M | 47.04% | 58.71% | 38.01% | -$1.1M |
|
ALDX
Aldeyra Therapeutics, Inc.
|
-$63.7K | -$8M | -53.75% | -66.61% | -- | -$7M |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$90.5M | $8.5M | -15.75% | -29.4% | 8.59% | -$1.8M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
MRKR
Marker Therapeutics, Inc.
|
-- | -$2.1M | -103.04% | -103.04% | -173.31% | -$2.7M |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$51.6M | -$31.3M | -16.2% | -16.55% | -55.61% | -$31.8M |
ADMA Biologics, Inc. vs. Competitors
-
Which has Higher Returns ADMA or ALDX?
Aldeyra Therapeutics, Inc. has a net margin of 27.14% compared to ADMA Biologics, Inc.'s net margin of --. ADMA Biologics, Inc.'s return on equity of 58.71% beat Aldeyra Therapeutics, Inc.'s return on equity of -66.61%.
Company Gross Margin Earnings Per Share Invested Capital ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M ALDXAldeyra Therapeutics, Inc.-- -$0.13 $64.8M -
What do Analysts Say About ADMA or ALDX?
ADMA Biologics, Inc. has a consensus price target of $25.67, signalling upside risk potential of 47.51%. On the other hand Aldeyra Therapeutics, Inc. has an analysts' consensus of $9.67 which suggests that it could grow by 85.19%. Given that Aldeyra Therapeutics, Inc. has higher upside potential than ADMA Biologics, Inc., analysts believe Aldeyra Therapeutics, Inc. is more attractive than ADMA Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ADMAADMA Biologics, Inc.3 0 0 ALDXAldeyra Therapeutics, Inc.4 0 0 -
Is ADMA or ALDX More Risky?
ADMA Biologics, Inc. has a beta of 0.466, which suggesting that the stock is 53.393% less volatile than S&P 500. In comparison Aldeyra Therapeutics, Inc. has a beta of 0.858, suggesting its less volatile than the S&P 500 by 14.241%.
-
Which is a Better Dividend Stock ADMA or ALDX?
ADMA Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aldeyra Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics, Inc. pays -- of its earnings as a dividend. Aldeyra Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADMA or ALDX?
ADMA Biologics, Inc. quarterly revenues are $134.2M, which are larger than Aldeyra Therapeutics, Inc. quarterly revenues of --. ADMA Biologics, Inc.'s net income of $36.4M is higher than Aldeyra Therapeutics, Inc.'s net income of -$7.7M. Notably, ADMA Biologics, Inc.'s price-to-earnings ratio is 20.43x while Aldeyra Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics, Inc. is 8.76x versus -- for Aldeyra Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADMAADMA Biologics, Inc.8.76x 20.43x $134.2M $36.4M ALDXAldeyra Therapeutics, Inc.-- -- -- -$7.7M
-
Which has Higher Returns ADMA or ARQT?
Arcutis Biotherapeutics, Inc. has a net margin of 27.14% compared to ADMA Biologics, Inc.'s net margin of 7.47%. ADMA Biologics, Inc.'s return on equity of 58.71% beat Arcutis Biotherapeutics, Inc.'s return on equity of -29.4%.
Company Gross Margin Earnings Per Share Invested Capital ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M ARQTArcutis Biotherapeutics, Inc.91.25% $0.06 $271.8M -
What do Analysts Say About ADMA or ARQT?
ADMA Biologics, Inc. has a consensus price target of $25.67, signalling upside risk potential of 47.51%. On the other hand Arcutis Biotherapeutics, Inc. has an analysts' consensus of $31.63 which suggests that it could grow by 18.67%. Given that ADMA Biologics, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe ADMA Biologics, Inc. is more attractive than Arcutis Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ADMAADMA Biologics, Inc.3 0 0 ARQTArcutis Biotherapeutics, Inc.4 1 0 -
Is ADMA or ARQT More Risky?
ADMA Biologics, Inc. has a beta of 0.466, which suggesting that the stock is 53.393% less volatile than S&P 500. In comparison Arcutis Biotherapeutics, Inc. has a beta of 1.710, suggesting its more volatile than the S&P 500 by 70.962%.
-
Which is a Better Dividend Stock ADMA or ARQT?
ADMA Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcutis Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics, Inc. pays -- of its earnings as a dividend. Arcutis Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADMA or ARQT?
ADMA Biologics, Inc. quarterly revenues are $134.2M, which are larger than Arcutis Biotherapeutics, Inc. quarterly revenues of $99.2M. ADMA Biologics, Inc.'s net income of $36.4M is higher than Arcutis Biotherapeutics, Inc.'s net income of $7.4M. Notably, ADMA Biologics, Inc.'s price-to-earnings ratio is 20.43x while Arcutis Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics, Inc. is 8.76x versus 10.71x for Arcutis Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADMAADMA Biologics, Inc.8.76x 20.43x $134.2M $36.4M ARQTArcutis Biotherapeutics, Inc.10.71x -- $99.2M $7.4M
-
Which has Higher Returns ADMA or CRMD?
CorMedix, Inc. has a net margin of 27.14% compared to ADMA Biologics, Inc.'s net margin of 49.9%. ADMA Biologics, Inc.'s return on equity of 58.71% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About ADMA or CRMD?
ADMA Biologics, Inc. has a consensus price target of $25.67, signalling upside risk potential of 47.51%. On the other hand CorMedix, Inc. has an analysts' consensus of $15.57 which suggests that it could grow by 109.29%. Given that CorMedix, Inc. has higher upside potential than ADMA Biologics, Inc., analysts believe CorMedix, Inc. is more attractive than ADMA Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ADMAADMA Biologics, Inc.3 0 0 CRMDCorMedix, Inc.4 0 0 -
Is ADMA or CRMD More Risky?
ADMA Biologics, Inc. has a beta of 0.466, which suggesting that the stock is 53.393% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.358, suggesting its more volatile than the S&P 500 by 35.753%.
-
Which is a Better Dividend Stock ADMA or CRMD?
ADMA Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADMA or CRMD?
ADMA Biologics, Inc. quarterly revenues are $134.2M, which are larger than CorMedix, Inc. quarterly revenues of $104.3M. ADMA Biologics, Inc.'s net income of $36.4M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, ADMA Biologics, Inc.'s price-to-earnings ratio is 20.43x while CorMedix, Inc.'s PE ratio is 3.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics, Inc. is 8.76x versus 2.51x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADMAADMA Biologics, Inc.8.76x 20.43x $134.2M $36.4M CRMDCorMedix, Inc.2.51x 3.62x $104.3M $108.6M
-
Which has Higher Returns ADMA or MRKR?
Marker Therapeutics, Inc. has a net margin of 27.14% compared to ADMA Biologics, Inc.'s net margin of -162.11%. ADMA Biologics, Inc.'s return on equity of 58.71% beat Marker Therapeutics, Inc.'s return on equity of -103.04%.
Company Gross Margin Earnings Per Share Invested Capital ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M MRKRMarker Therapeutics, Inc.-- -$0.12 $18.4M -
What do Analysts Say About ADMA or MRKR?
ADMA Biologics, Inc. has a consensus price target of $25.67, signalling upside risk potential of 47.51%. On the other hand Marker Therapeutics, Inc. has an analysts' consensus of $7.87 which suggests that it could grow by 285.62%. Given that Marker Therapeutics, Inc. has higher upside potential than ADMA Biologics, Inc., analysts believe Marker Therapeutics, Inc. is more attractive than ADMA Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ADMAADMA Biologics, Inc.3 0 0 MRKRMarker Therapeutics, Inc.3 0 0 -
Is ADMA or MRKR More Risky?
ADMA Biologics, Inc. has a beta of 0.466, which suggesting that the stock is 53.393% less volatile than S&P 500. In comparison Marker Therapeutics, Inc. has a beta of 1.371, suggesting its more volatile than the S&P 500 by 37.092%.
-
Which is a Better Dividend Stock ADMA or MRKR?
ADMA Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Marker Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics, Inc. pays -- of its earnings as a dividend. Marker Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADMA or MRKR?
ADMA Biologics, Inc. quarterly revenues are $134.2M, which are larger than Marker Therapeutics, Inc. quarterly revenues of $1.2M. ADMA Biologics, Inc.'s net income of $36.4M is higher than Marker Therapeutics, Inc.'s net income of -$2M. Notably, ADMA Biologics, Inc.'s price-to-earnings ratio is 20.43x while Marker Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics, Inc. is 8.76x versus 5.53x for Marker Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADMAADMA Biologics, Inc.8.76x 20.43x $134.2M $36.4M MRKRMarker Therapeutics, Inc.5.53x -- $1.2M -$2M
-
Which has Higher Returns ADMA or VNDA?
Vanda Pharmaceuticals, Inc. has a net margin of 27.14% compared to ADMA Biologics, Inc.'s net margin of -40.15%. ADMA Biologics, Inc.'s return on equity of 58.71% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.
Company Gross Margin Earnings Per Share Invested Capital ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M VNDAVanda Pharmaceuticals, Inc.91.64% -$0.38 $476.9M -
What do Analysts Say About ADMA or VNDA?
ADMA Biologics, Inc. has a consensus price target of $25.67, signalling upside risk potential of 47.51%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $13.63 which suggests that it could grow by 68.21%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than ADMA Biologics, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than ADMA Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ADMAADMA Biologics, Inc.3 0 0 VNDAVanda Pharmaceuticals, Inc.3 1 0 -
Is ADMA or VNDA More Risky?
ADMA Biologics, Inc. has a beta of 0.466, which suggesting that the stock is 53.393% less volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.604, suggesting its less volatile than the S&P 500 by 39.647%.
-
Which is a Better Dividend Stock ADMA or VNDA?
ADMA Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADMA or VNDA?
ADMA Biologics, Inc. quarterly revenues are $134.2M, which are larger than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. ADMA Biologics, Inc.'s net income of $36.4M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, ADMA Biologics, Inc.'s price-to-earnings ratio is 20.43x while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics, Inc. is 8.76x versus 2.24x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADMAADMA Biologics, Inc.8.76x 20.43x $134.2M $36.4M VNDAVanda Pharmaceuticals, Inc.2.24x -- $56.3M -$22.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Goldman Sachs Going to Go Up?
Shares of financial giant Goldman Sachs (NYSE:GS) have soared by…
How High Will MSTR Stock Go?
After several months of pressure, shares of Bitcoin treasury Strategy…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
59
RGC alert for Jan 23
Regencell Bioscience Holdings Ltd. [RGC] is up 40.39% over the past day.
Buy
70
BNR alert for Jan 23
Burning Rock Biotech Ltd. [BNR] is up 33.29% over the past day.
Buy
76
HYMC alert for Jan 23
Hycroft Mining Holding Corp. [HYMC] is up 17.39% over the past day.
